May 29, 2018 7:30am EDT Rigel Announces Availability of TAVALISSE™ (fostamatinib disodium hexahydrate) in the U.S.
May 01, 2018 4:01pm EDT Rigel Announces First Quarter 2018 Financial Results and Provides Company Update
Apr 30, 2018 7:30am EDT TAVALISSE™ (fostamatinib disodium hexahydrate) Phase 3 Data Published in the American Journal of Hematology Describes Pivotal Data and Overall Response Rate Versus Placebo
Apr 24, 2018 7:30am EDT Rigel Announces Conference Call and Webcast to Report First Quarter 2018 Financial Results
Apr 17, 2018 4:51pm EDT Rigel Announces FDA Approval of TAVALISSE™ (fostamatinib disodium hexahydrate) for Chronic Immune Thrombocytopenia (ITP) in Adult Patients
Apr 03, 2018 7:00am EDT Rigel Announces Topline Data from Proof-of-Concept Phase 2 Study of Fostamatinib in IgA Nephropathy
Mar 06, 2018 4:01pm EST Rigel Announces Fourth Quarter and Year End 2017 Financial Results and Provides Company Update
